Ghrelin News and Research

RSS

Ghrelin is a hormone produced mainly by P/D1 cells lining the fundus of the human stomach and epsilon cells of the pancreas that stimulates appetite. Ghrelin levels increase before meals and decrease after meals. It is considered the counterpart of the hormone leptin, produced by adipose tissue, which induces satiation when present at higher levels. Ghrelin is also produced in the hypothalamic arcuate nucleus where it stimulates the secretion of growth hormone from the anterior pituitary gland.

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Ghrelin hormone supplement increases sexual activity in mice

Swedish studies show that mice that receive a supplement of the "appetite hormone" ghrelin increase their sexual activity. Whether the hormone has the same impact on humans is unknown - but if it does, the researchers may have found the key to future treatments for sex abuse.

28 Jan 2015

Study suggests link between neonatal ghrelin and obesity risk

Our subconscious motivation to eat is powerfully and dynamically regulated by hormone signals. The gut-derived hormone ghrelin is one such key regulator, promoting appetite through its effects on neurons in a small region of the brain called the hypothalamus.

21 Jan 2015

Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers and overweight or obese subjects.

10 Dec 2014

Ghrelin has potential to stimulate alcohol craving, study reveals

Ghrelin is a hormone released by the stomach and it stimulates appetite and food intake. Alcohol is commonly viewed as a psychoactive substance that primarily affects brain function, but it is also a highly caloric food.

30 Oct 2014

Researchers demonstrate involvement of ClpB protein in eating disorders

Eating disorders (ED) such as anorexia nervosa, bulimia, and binge eating disorder affect approximately 5-10% of the general population, but the biological mechanisms involved are unknown. Researchers at Inserm Unit 1073, "Nutrition, inflammation and dysfunction of the gut-brain axis" (Inserm/University of Rouen) have demonstrated the involvement of a protein produced by some intestinal bacteria that may be the source of these disorders.

7 Oct 2014

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.

25 Sep 2014

Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris Inc. today announced a strategic co-promotion services agreement with ASCEND Therapeutics US, LLC.

5 Aug 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Proteins causing daytime sleepiness also play crucial role in bone formation

Orexin proteins, which are blamed for spontaneous daytime sleepiness, also play a crucial role in bone formation, according to findings by UT Southwestern Medical Center researchers.

13 Jun 2014

People with obesity gene FTO tend to gain more weight as they age

A new study from Uppsala University demonstrates that elderly humans carrying a common variant of the fat mass and obesity gene FTO also have a shifted endocrine balance. Low blood concentrations of the satiety hormone leptin and high blood concentrations of the hunger promoting hormone ghrelin makes carriers of the FTO gene put on weight.

12 Jun 2014

New data shows adult America is 55% obese, not 35%

On the heels of the wake-up call from 'FED UP', the just released documentary on obesity, it is no surprise that the CDC's (U.S. Center for Disease Control) obesity statistics are grossly under reported. Meredith

6 Jun 2014

Yale researchers find that hormone leptin may help treat metabolic disorders

Twenty years after the hormone leptin was found to regulate metabolism, appetite, and weight through brain cells called neurons, Yale School of Medicine researchers have found that the hormone also acts on other types of cells to control appetite.

2 Jun 2014

UT Southwestern researchers identify potential new treatment for depression

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression.

23 Apr 2014

Wen Dan Tang significantly reduces insomnia-related anxiety

Ghrelin, a brain-gut peptide that induces anxiety and other abnormal emotions, contributes to the effects of insomnia on emotional behavior. In contrast, the traditional Chinese Medicine remedy Wen Dan Tang reduces insomnia-related anxiety, which may perhaps correspond to changes in the brain-gut axis.

1 Apr 2014

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Georgia Regents Medical Center is among about a dozen centers nationally exploring the potential of a new drug that may offer relief to people with Parkinson's who have failed standard approaches to treating constipation.

5 Mar 2014

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.

7 Jan 2014

Obesity is an expensive problem, says bariatric surgeon

As a preeminent expert in the field of obesity surgery, board-certified bariatric surgeon Michael Feiz, M.D., F.A.C.S, has personally seen the physical, emotional and financial toll that obesity takes on his patients.

31 Dec 2013

Embolizing left gastric artery may be potential bariatric treatment for weight loss

A new study reports that individuals who underwent embolization of the left gastric artery for gastrointestinal bleeding experienced a 7.9 percent decrease in body weight three months after the procedure.

26 Nov 2013